Charles Rivers Makes Organizational Changes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charles Rivers Makes Organizational Changes



Charles River Laboratories reports organizational changes, which are designed to improve the company’s productivity initiatives and promote the global management of its Research Models and Services (RMS) and Preclinical Services (PCS) businesses. The respective organizational changes are as follows:

Jörg Geller, DVM, PhD, previously corporate executive vice-president and president, European & Asian Operations, will now directly oversee a global initiative to improve efficiency and drive increased productivity across all of Charles River’s businesses. In his new role, Geller will assume the title of corporate executive vice-president global productivity and efficiency.

In conjunction with Geller assuming this new role, Davide Molho, DVM, previously corporate executive vice-president and president, North American Operations, will assume a broader range of responsibilities with global oversight of the RMS and PCS businesses. In his new role, Molho will assume the title of corporate executive vice-president and president, Global Research Models & Services and Preclinical Services Operations.

Colin Dunn, PhD, has been promoted to the position of corporate senior vice-president and general manager, RMS, Europe and Asia.  Dunn was previously responsible for European RMS operations, and in his expanded role, will oversee all of the company’s RMS operations in Europe, Japan, and China. Dunn will report to Molho, as will Brian Bathgate, corporate senior vice-president, European Preclinical Services. Bathgate will continue to oversee European preclinical operations as well as global PCS Laboratory Services.

Emily Hickey, who joined Charles River in October 2013 as corporate vice-president, In Vivo Discovery Research Services, will now report directly to Chairman, President, and CEO James Foster. This reporting change parallels the organizational structure that was previously established for the company’s endotoxin and microbial detection business. Foster Jordan, corporate senior vice-president, endotoxin and microbial detection, will continue to report directly to Foster.

Source: Charles River Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here